Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Yohimbine is an alpha 2 adrenergic receptor antagonist, which has been shown to counteract the CNS depressant effects of alpha 2 receptor agonists in a number of species. Recently, our laboratory identified yohimbine in the absence of detectable concentrations of an alpha 2 agonist in a regulatory sample collected from a horse racing in California. This coupled with anecdotal reports of CNS stimulation and documented reports of cardiovascular changes when administered in conjunction with an agonist led us to investigate the pharmacokinetics and pharmacodynamics of yohimbine when administered alone. Nine healthy adult horses received a single intravenous dose of 0.1, 0.2, and 0.4mg/kg yohimbine. Blood samples were collected at time 0 (prior to drug administration) and at various times up to 24h postdrug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry (LC-MS), and resulting data analyzed using both noncompartmental and compartmental analysis. Peak plasma concentrations were 106.0±28.9, 156.7±34.3, and 223.0±44.5ng/mL for doses of 0.1, 0.2, and 0.4mg/kg, respectively. Immediately following administration, two horses showed signs of sedation, one horse appeared excited, while the other six appeared behaviorally unaffected. Episodes of tachycardia were noted within minutes of administration for all horses at all doses; however, there was no correlation between behavioral responses and episodes of increased heart rate. Sixty-three percent of the horses (8, 6, and 4 of the 9 horses in the 0.1, 0.2, and 0.4mg/kg dose groups, respectively) exhibited second-degree atrial-ventricular conduction blocks and bradycardia prior to drug administration that transiently improved or disappeared upon administration of yohimbine. Gastrointestinal sounds were transiently increased following all doses.

Original languageEnglish (US)
Pages (from-to)359-366
Number of pages8
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume34
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

yohimbine
Yohimbine
pharmacology
pharmacokinetics
Horses
Pharmacokinetics
horses
dosage
agonists
Adrenergic alpha-2 Receptor Antagonists
Central Nervous System Depressants
drugs
sedation
Bradycardia
Tachycardia
sampling
Liquid Chromatography
Pharmaceutical Preparations
liquid chromatography
heart rate

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

@article{ab4346e3f63147f289255f97901f4407,
title = "Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse",
abstract = "Yohimbine is an alpha 2 adrenergic receptor antagonist, which has been shown to counteract the CNS depressant effects of alpha 2 receptor agonists in a number of species. Recently, our laboratory identified yohimbine in the absence of detectable concentrations of an alpha 2 agonist in a regulatory sample collected from a horse racing in California. This coupled with anecdotal reports of CNS stimulation and documented reports of cardiovascular changes when administered in conjunction with an agonist led us to investigate the pharmacokinetics and pharmacodynamics of yohimbine when administered alone. Nine healthy adult horses received a single intravenous dose of 0.1, 0.2, and 0.4mg/kg yohimbine. Blood samples were collected at time 0 (prior to drug administration) and at various times up to 24h postdrug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry (LC-MS), and resulting data analyzed using both noncompartmental and compartmental analysis. Peak plasma concentrations were 106.0±28.9, 156.7±34.3, and 223.0±44.5ng/mL for doses of 0.1, 0.2, and 0.4mg/kg, respectively. Immediately following administration, two horses showed signs of sedation, one horse appeared excited, while the other six appeared behaviorally unaffected. Episodes of tachycardia were noted within minutes of administration for all horses at all doses; however, there was no correlation between behavioral responses and episodes of increased heart rate. Sixty-three percent of the horses (8, 6, and 4 of the 9 horses in the 0.1, 0.2, and 0.4mg/kg dose groups, respectively) exhibited second-degree atrial-ventricular conduction blocks and bradycardia prior to drug administration that transiently improved or disappeared upon administration of yohimbine. Gastrointestinal sounds were transiently increased following all doses.",
author = "Knych, {Heather K} and Eugene Steffey and Stanley, {Scott D}",
year = "2011",
month = "8",
doi = "10.1111/j.1365-2885.2010.01234.x",
language = "English (US)",
volume = "34",
pages = "359--366",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse

AU - Knych, Heather K

AU - Steffey, Eugene

AU - Stanley, Scott D

PY - 2011/8

Y1 - 2011/8

N2 - Yohimbine is an alpha 2 adrenergic receptor antagonist, which has been shown to counteract the CNS depressant effects of alpha 2 receptor agonists in a number of species. Recently, our laboratory identified yohimbine in the absence of detectable concentrations of an alpha 2 agonist in a regulatory sample collected from a horse racing in California. This coupled with anecdotal reports of CNS stimulation and documented reports of cardiovascular changes when administered in conjunction with an agonist led us to investigate the pharmacokinetics and pharmacodynamics of yohimbine when administered alone. Nine healthy adult horses received a single intravenous dose of 0.1, 0.2, and 0.4mg/kg yohimbine. Blood samples were collected at time 0 (prior to drug administration) and at various times up to 24h postdrug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry (LC-MS), and resulting data analyzed using both noncompartmental and compartmental analysis. Peak plasma concentrations were 106.0±28.9, 156.7±34.3, and 223.0±44.5ng/mL for doses of 0.1, 0.2, and 0.4mg/kg, respectively. Immediately following administration, two horses showed signs of sedation, one horse appeared excited, while the other six appeared behaviorally unaffected. Episodes of tachycardia were noted within minutes of administration for all horses at all doses; however, there was no correlation between behavioral responses and episodes of increased heart rate. Sixty-three percent of the horses (8, 6, and 4 of the 9 horses in the 0.1, 0.2, and 0.4mg/kg dose groups, respectively) exhibited second-degree atrial-ventricular conduction blocks and bradycardia prior to drug administration that transiently improved or disappeared upon administration of yohimbine. Gastrointestinal sounds were transiently increased following all doses.

AB - Yohimbine is an alpha 2 adrenergic receptor antagonist, which has been shown to counteract the CNS depressant effects of alpha 2 receptor agonists in a number of species. Recently, our laboratory identified yohimbine in the absence of detectable concentrations of an alpha 2 agonist in a regulatory sample collected from a horse racing in California. This coupled with anecdotal reports of CNS stimulation and documented reports of cardiovascular changes when administered in conjunction with an agonist led us to investigate the pharmacokinetics and pharmacodynamics of yohimbine when administered alone. Nine healthy adult horses received a single intravenous dose of 0.1, 0.2, and 0.4mg/kg yohimbine. Blood samples were collected at time 0 (prior to drug administration) and at various times up to 24h postdrug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry (LC-MS), and resulting data analyzed using both noncompartmental and compartmental analysis. Peak plasma concentrations were 106.0±28.9, 156.7±34.3, and 223.0±44.5ng/mL for doses of 0.1, 0.2, and 0.4mg/kg, respectively. Immediately following administration, two horses showed signs of sedation, one horse appeared excited, while the other six appeared behaviorally unaffected. Episodes of tachycardia were noted within minutes of administration for all horses at all doses; however, there was no correlation between behavioral responses and episodes of increased heart rate. Sixty-three percent of the horses (8, 6, and 4 of the 9 horses in the 0.1, 0.2, and 0.4mg/kg dose groups, respectively) exhibited second-degree atrial-ventricular conduction blocks and bradycardia prior to drug administration that transiently improved or disappeared upon administration of yohimbine. Gastrointestinal sounds were transiently increased following all doses.

UR - http://www.scopus.com/inward/record.url?scp=79960104770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960104770&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2885.2010.01234.x

DO - 10.1111/j.1365-2885.2010.01234.x

M3 - Article

C2 - 20950351

AN - SCOPUS:79960104770

VL - 34

SP - 359

EP - 366

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 4

ER -